VELCURA MANAGEMENT TEAM Velcura has a strong and growing multi-talented management team that is led by Dr. Michael Long and Mary Ann Alger, who established the company in March 2001. Michael Long, Ph.D., President and CEO. The Founder, and scientific inventor of Velcura Therapeutics™, Inc.’s patented technology, Dr. Michael Long, has worked in the area of cell and molecular biology for more than two decades and has received more than $10 million in funding for his research from the National Institutes of Health. He received an additional $3.3 million in funding from the Michigan Life Sciences Corridor in 2002. As a professor at the University of Michigan, he developed the technology for bone cell analysis and for forming human bone outside the body that the University has exclusively licensed to Velcura. Dr. Long has done extensive consulting for startup and leading biotechnology firms, as well as major pharmaceutical firms. In addition, he serves on the Executive Committee of the national board of the Leukemia and Lymphoma Society. This association has provided experience in corporate oversight, fundraising, strategic planning, and legal affairs. He also has experience in directing large for-profit clinical laboratories. Mary Ann Alger, CFO. Velcura’s Cofounder and Chief Financial Officer Mary Ann Alger has 20 years of experience in venture capital, corporate finance, and small business consulting. Ms. Alger has raised three equity investment funds and originated and closed numerous equity investments and debt financings. Her business experience spans a wide range of industries. Also an adjunct instructor at the University of Michigan Business School, she serves on the school’s Wolverine Venture Fund advisory board. She has undergraduate degrees in International Business and Spanish from Auburn University and a Master of Business Administration degree from the University of Miami. She also completed an executive program at Johns Hopkins University's School of Advanced International Studies.